<p>随着 ASX 200 指数徘徊在 9000 点以上，交易者在全球经济事件和本地财报的背景下谨慎地应对市场。尽管存在一些犹豫，某些小型股票因其增长和价值潜力而继续吸引投资者的关注。尽管 “便士股票” 这一术语较为陈旧，但它们仍然代表着在一些不太知名的公司中，具有强大基本面的投资机会，这些公司能够提供稳定性和上涨潜力。</p>
<h3>澳大利亚十大便士股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$2.59</td>
<td>A$1.2218 亿</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>GTN (ASX:GTN)</td>
<td>A$0.40</td>
<td>A$7627 万</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$3.04</td>
<td>A$4.6871 亿</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>SHAPE Australia (ASX:SHA)</td>
<td>A$4.31</td>
<td>A$3.5491 亿</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$2.79</td>
<td>A$31.8 亿</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Regal Partners (ASX:RPL)</td>
<td>A$3.02</td>
<td>A$10.2 亿</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Bravura Solutions (ASX:BVS)</td>
<td>A$2.28</td>
<td>A$10.2 亿</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Austco Healthcare (ASX:AHC)</td>
<td>A$0.37</td>
<td>A$1.3523 亿</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Austin Engineering (ASX:ANG)</td>
<td>A$0.315</td>
<td>A$1.9547 亿</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>CTI Logistics (ASX:CLX)</td>
<td>A$1.855</td>
<td>A$1.4941 亿</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
<p>点击这里查看我们 ASX 便士股票筛选器中的 455 只股票的完整列表。</p>
<p>下面我们重点介绍几只我们独家的筛选器中的最爱。</p>
<h2>AMA Group (ASX:AMA)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> AMA Group Limited 在澳大利亚和新西兰运营碰撞修复业务，市值为 4.4956 亿澳元。</p>
<p><strong>运营：</strong> 公司未报告具体的收入细分。</p>
<p><strong>市值：</strong> A$4.4956 亿</p>
<p>AMA Group 的市值为 4.4956 亿澳元，专注于澳大利亚和新西兰的碰撞修复行业。尽管尚未盈利，但在过去五年中其亏损年均减少 21%，并保持了 7.2% 的净负债与股本比率。该公司以显著低于其估计公允价值的价格交易，分析师预计其价格有 22.3% 的上涨潜力。最近的财报显示，截至 2025 年 6 月的年度销售额增长至 10.1 亿澳元，而净亏损从 763 万澳元略微改善至 747 万澳元。</p>
<ul>
<li>在这里深入了解 AMA Group 的具体情况，查看我们的全面资产负债表健康报告。</li>
<li>通过查看我们的增长报告，获取 AMA Group 未来方向的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d903c2f6-0fdf-4047-a309-1525f5fdf3e3/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d903c2f6-0fdf-4047-a309-1525f5fdf3e3/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 8 月的 ASX:AMA 负债与股本历史及分析</p>
<h2>Peet (ASX:PPC)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Peet Limited 在澳大利亚收购、开发和销售住宅用地，市值为 8.0055 亿澳元。</p>
<p><strong>运营：</strong> Peet 的收入主要来自公司自有项目（3.1324 亿澳元），辅以基金管理（5639 万澳元）和联合安排（5188 万澳元）。</p>
<p><strong>市值：</strong> A$8.0055 亿</p>
<p>Peet Limited 的市值为 8.0055 亿澳元，目前正在高盛的战略审查下，旨在优化其资产基础，以应对有利的市场条件。该公司报告了 2025 财年的强劲收益增长，销售额达到 4.1479 亿澳元，净收入为 5847 万澳元，反映出澳大利亚住宅物业市场的强劲需求。尽管负债水平较高（净负债与股本比率为 45.8%），但 Peet 的债务得到了经营现金流的良好覆盖，利息支付也由 EBIT 的 10.7 倍轻松管理。然而，管理团队相对较新，平均任期为一年。</p>
<ul>
<li>在这里阅读我们的资产负债表健康报告，深入了解 Peet 的表现。</li>
<li>查看我们的历史表现报告，以获取 Peet 的业绩记录的见解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/993b423f-f3f9-4d37-9bcf-21b98c0b895b/chart/debt-equity-history-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/993b423f-f3f9-4d37-9bcf-21b98c0b895b/chart/debt-equity-history-analysis"/></p>
<p>截至 2025 年 8 月的 ASX:PPC 负债与股本历史及分析</p>
<h2>XRF Scientific (ASX:XRF)</h2>
<p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
<p><strong>概述：</strong> XRF Scientific Limited 在澳大利亚、加拿大和欧洲制造和销售贵金属产品、专业化学品和仪器，市值为 3.1340 亿澳元，服务于科学、分析、建筑材料和矿业行业。</p>
<p><strong>运营：</strong> 公司的收入来自三个主要细分市场：消耗品（1926 万澳元）、贵金属（2151 万澳元）和资本设备（2256 万澳元）。</p>
<p><strong>市值：</strong> A$3.1340 亿</p>
<p>XRF Scientific 的市值为 3.1340 亿澳元，尽管销售增长温和，但其财务韧性得到了体现。其 2025 财年的最新财报显示，净收入从前一年的 889 万澳元上升至 1038 万澳元，利润率改善至 17.5%。公司的强大资产负债表表明，短期资产超过负债，且负债与股本比率在五年内从 14.5% 降至 4.4%，同时利息支付得到了良好覆盖，经营现金流显著超过债务水平。此外，XRF 经验丰富的管理层和董事会增强了其在行业波动中的运营稳定性。</p>
<ul>
<li>在这里深入了解 XRF Scientific 的全面分析健康报告。</li>
<li>了解 XRF Scientific 的未来增长轨迹。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9b63580b-4082-4ba3-bd48-ba43082e3621/chart/financial-position-analysis?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9b63580b-4082-4ba3-bd48-ba43082e3621/chart/financial-position-analysis"/></p>
<p>截至 2025 年 8 月的 ASX:XRF 财务状况分析</p>
<h2>关键要点</h2>
<ul>
<li>在这里查看我们完整的 455 只 ASX 便士股票目录。</li>
<li>寻找其他投资？这 13 家公司在 COVID 之后生存并蓬勃发展，具备应对特朗普关税的正确要素。在您的投资组合感受到贸易战压力之前，了解原因。</li>
</ul>
<p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

<p>随着 ASX 200 指数保持在 9000 点以上，交易者们开始关注具有增长潜力的低价股。值得注意的公司包括 AMA Group（ASX:AMA），该公司在碰撞修复领域运营，市值为 4.4956 亿澳元，显示出亏损减少和潜在的价格上涨。Peet Limited（ASX:PPC）正在进行战略审查，住宅土地开发方面的收益强劲。XRF Scientific（ASX:XRF）展现出财务韧性，市值为 3.134 亿澳元，利润率有所改善。这些公司突显了当前市场环境中的机会</p>

<p>As the ASX 200 hovers just above 9,000 points, traders are cautiously navigating the market amid global economic events and local earnings reports. Despite some hesitancy, certain smaller stocks continue to capture investor attention due to their potential for growth and value. Penny stocks, though an old term, still represent opportunities in lesser-known companies with strong fundamentals that can offer both stability and upside potential.</p>
<div class="lb-trans"><p>随着 ASX 200 指数徘徊在 9000 点以上，交易者在全球经济事件和本地财报的背景下谨慎地应对市场。尽管存在一些犹豫，某些小型股票因其增长和价值潜力而继续吸引投资者的关注。尽管 “便士股票” 这一术语较为陈旧，但它们仍然代表着在一些不太知名的公司中，具有强大基本面的投资机会，这些公司能够提供稳定性和上涨潜力。</p>
</div><h3>Top 10 Penny Stocks In Australia</h3>
<div class="lb-trans"><h3>澳大利亚十大便士股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Share Price</strong></td>
<td><strong>Market Cap</strong></td>
<td><strong>Rewards &amp; Risks</strong></td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$2.59</td>
<td>A$122.18M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>GTN (ASX:GTN)</td>
<td>A$0.40</td>
<td>A$76.27M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$3.04</td>
<td>A$468.71M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>SHAPE Australia (ASX:SHA)</td>
<td>A$4.31</td>
<td>A$354.91M</td>
<td>✅ 3 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$2.79</td>
<td>A$3.18B</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Regal Partners (ASX:RPL)</td>
<td>A$3.02</td>
<td>A$1.02B</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
<tr>
<td>Bravura Solutions (ASX:BVS)</td>
<td>A$2.28</td>
<td>A$1.02B</td>
<td>✅ 3 ⚠️ 3 View Analysis &gt;</td>
</tr>
<tr>
<td>Austco Healthcare (ASX:AHC)</td>
<td>A$0.37</td>
<td>A$135.23M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>Austin Engineering (ASX:ANG)</td>
<td>A$0.315</td>
<td>A$195.47M</td>
<td>✅ 4 ⚠️ 1 View Analysis &gt;</td>
</tr>
<tr>
<td>CTI Logistics (ASX:CLX)</td>
<td>A$1.855</td>
<td>A$149.41M</td>
<td>✅ 4 ⚠️ 2 View Analysis &gt;</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名称</strong></td>
<td><strong>股价</strong></td>
<td><strong>市值</strong></td>
<td><strong>收益与风险</strong></td>
</tr>
<tr>
<td>EZZ Life Science Holdings (ASX:EZZ)</td>
<td>A$2.59</td>
<td>A$1.2218 亿</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>GTN (ASX:GTN)</td>
<td>A$0.40</td>
<td>A$7627 万</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>IVE Group (ASX:IGL)</td>
<td>A$3.04</td>
<td>A$4.6871 亿</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>SHAPE Australia (ASX:SHA)</td>
<td>A$4.31</td>
<td>A$3.5491 亿</td>
<td>✅ 3 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>West African Resources (ASX:WAF)</td>
<td>A$2.79</td>
<td>A$31.8 亿</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Regal Partners (ASX:RPL)</td>
<td>A$3.02</td>
<td>A$10.2 亿</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
<tr>
<td>Bravura Solutions (ASX:BVS)</td>
<td>A$2.28</td>
<td>A$10.2 亿</td>
<td>✅ 3 ⚠️ 3 查看分析</td>
</tr>
<tr>
<td>Austco Healthcare (ASX:AHC)</td>
<td>A$0.37</td>
<td>A$1.3523 亿</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>Austin Engineering (ASX:ANG)</td>
<td>A$0.315</td>
<td>A$1.9547 亿</td>
<td>✅ 4 ⚠️ 1 查看分析</td>
</tr>
<tr>
<td>CTI Logistics (ASX:CLX)</td>
<td>A$1.855</td>
<td>A$1.4941 亿</td>
<td>✅ 4 ⚠️ 2 查看分析</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 455 stocks from our ASX Penny Stocks screener.</p>
<div class="lb-trans"><p>点击这里查看我们 ASX 便士股票筛选器中的 455 只股票的完整列表。</p>
</div><p>Below we spotlight a couple of our favorites from our exclusive screener.</p>
<div class="lb-trans"><p>下面我们重点介绍几只我们独家的筛选器中的最爱。</p>
</div><h2>AMA Group (ASX:AMA)</h2>
<div class="lb-trans"><h2>AMA Group (ASX:AMA)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> AMA Group Limited operates a collision repair business across Australia and New Zealand, with a market cap of A$449.56 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> AMA Group Limited 在澳大利亚和新西兰运营碰撞修复业务，市值为 4.4956 亿澳元。</p>
</div><p><strong>Operations:</strong> No specific revenue segments are reported for the company.</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司未报告具体的收入细分。</p>
</div><p><strong>Market Cap:</strong> A$449.56M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$4.4956 亿</p>
</div><p>AMA Group, with a market cap of A$449.56 million, operates in the collision repair sector across Australia and New Zealand. Despite being unprofitable, it has reduced losses by 21% annually over the past five years and maintains a satisfactory net debt to equity ratio of 7.2%. The company trades at a significant discount to its estimated fair value and analysts anticipate a potential price increase of 22.3%. Recent earnings show sales growth to A$1.01 billion for the year ended June 2025, while net loss slightly improved from A$7.63 million to A$7.47 million year-on-year.</p>
<div class="lb-trans"><p>AMA Group 的市值为 4.4956 亿澳元，专注于澳大利亚和新西兰的碰撞修复行业。尽管尚未盈利，但在过去五年中其亏损年均减少 21%，并保持了 7.2% 的净负债与股本比率。该公司以显著低于其估计公允价值的价格交易，分析师预计其价格有 22.3% 的上涨潜力。最近的财报显示，截至 2025 年 6 月的年度销售额增长至 10.1 亿澳元，而净亏损从 763 万澳元略微改善至 747 万澳元。</p>
</div><ul>
<li>Dive into the specifics of AMA Group here with our thorough balance sheet health report.</li>
<li>Gain insights into AMA Group's future direction by reviewing our growth report.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里深入了解 AMA Group 的具体情况，查看我们的全面资产负债表健康报告。</li>
<li>通过查看我们的增长报告，获取 AMA Group 未来方向的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d903c2f6-0fdf-4047-a309-1525f5fdf3e3/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/d903c2f6-0fdf-4047-a309-1525f5fdf3e3/chart/debt-equity-history-analysis"/></p>
<p>ASX:AMA Debt to Equity History and Analysis as at Aug 2025</p>
<div class="lb-trans"><p>截至 2025 年 8 月的 ASX:AMA 负债与股本历史及分析</p>
</div><h2>Peet (ASX:PPC)</h2>
<div class="lb-trans"><h2>Peet (ASX:PPC)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Peet Limited acquires, develops, and markets residential land in Australia with a market cap of A$800.55 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Peet Limited 在澳大利亚收购、开发和销售住宅用地，市值为 8.0055 亿澳元。</p>
</div><p><strong>Operations:</strong> Peet's revenue is primarily derived from Company Owned Projects (A$313.24 million), complemented by Funds Management (A$56.39 million) and Joint Arrangements (A$51.88 million).</p>
<div class="lb-trans"><p><strong>运营：</strong> Peet 的收入主要来自公司自有项目（3.1324 亿澳元），辅以基金管理（5639 万澳元）和联合安排（5188 万澳元）。</p>
</div><p><strong>Market Cap:</strong> A$800.55M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$8.0055 亿</p>
</div><p>Peet Limited, with a market cap of A$800.55 million, is navigating a strategic review led by Goldman Sachs to optimize its asset base amidst favorable market conditions. The company reported robust earnings growth for FY25, with sales reaching A$414.79 million and net income at A$58.47 million, reflecting strong demand in the Australian residential property sector. Despite high debt levels (net debt to equity ratio of 45.8%), Peet's debt is well-covered by operating cash flow and interest payments are comfortably managed by EBIT coverage of 10.7x. However, the management team is relatively new with an average tenure of one year.</p>
<div class="lb-trans"><p>Peet Limited 的市值为 8.0055 亿澳元，目前正在高盛的战略审查下，旨在优化其资产基础，以应对有利的市场条件。该公司报告了 2025 财年的强劲收益增长，销售额达到 4.1479 亿澳元，净收入为 5847 万澳元，反映出澳大利亚住宅物业市场的强劲需求。尽管负债水平较高（净负债与股本比率为 45.8%），但 Peet 的债务得到了经营现金流的良好覆盖，利息支付也由 EBIT 的 10.7 倍轻松管理。然而，管理团队相对较新，平均任期为一年。</p>
</div><ul>
<li>Get an in-depth perspective on Peet's performance by reading our balance sheet health report here.</li>
<li>Review our historical performance report to gain insights into Peet's track record.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里阅读我们的资产负债表健康报告，深入了解 Peet 的表现。</li>
<li>查看我们的历史表现报告，以获取 Peet 的业绩记录的见解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/993b423f-f3f9-4d37-9bcf-21b98c0b895b/chart/debt-equity-history-analysis" alt="" original-src="https://images.simplywall.st/company/993b423f-f3f9-4d37-9bcf-21b98c0b895b/chart/debt-equity-history-analysis"/></p>
<p>ASX:PPC Debt to Equity History and Analysis as at Aug 2025</p>
<div class="lb-trans"><p>截至 2025 年 8 月的 ASX:PPC 负债与股本历史及分析</p>
</div><h2>XRF Scientific (ASX:XRF)</h2>
<div class="lb-trans"><h2>XRF Scientific (ASX:XRF)</h2>
</div><p><strong>Simply Wall St Financial Health Rating:</strong> ★★★★★★</p>
<div class="lb-trans"><p><strong>Simply Wall St 财务健康评级：</strong> ★★★★★★</p>
</div><p><strong>Overview:</strong> XRF Scientific Limited manufactures and markets precious metal products, specialized chemicals, and instruments for the scientific, analytical, construction material, and mining industries across Australia, Canada, and Europe with a market cap of A$313.40 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> XRF Scientific Limited 在澳大利亚、加拿大和欧洲制造和销售贵金属产品、专业化学品和仪器，市值为 3.1340 亿澳元，服务于科学、分析、建筑材料和矿业行业。</p>
</div><p><strong>Operations:</strong> The company's revenue is derived from three main segments: Consumables (A$19.26 million), Precious Metals (A$21.51 million), and Capital Equipment (A$22.56 million).</p>
<div class="lb-trans"><p><strong>运营：</strong> 公司的收入来自三个主要细分市场：消耗品（1926 万澳元）、贵金属（2151 万澳元）和资本设备（2256 万澳元）。</p>
</div><p><strong>Market Cap:</strong> A$313.4M</p>
<div class="lb-trans"><p><strong>市值：</strong> A$3.1340 亿</p>
</div><p>XRF Scientific, with a market cap of A$313.40 million, has demonstrated financial resilience despite modest sales growth. Its recent earnings report for FY25 shows net income rising to A$10.38 million from A$8.89 million the previous year, highlighting improved profit margins at 17.5%. The company's strong balance sheet is evidenced by short-term assets exceeding liabilities and a reduced debt-to-equity ratio from 14.5% to 4.4% over five years, complemented by well-covered interest payments and operating cash flow surpassing debt levels significantly. Furthermore, XRF's seasoned management and board enhance its operational stability amidst industry volatility.</p>
<div class="lb-trans"><p>XRF Scientific 的市值为 3.1340 亿澳元，尽管销售增长温和，但其财务韧性得到了体现。其 2025 财年的最新财报显示，净收入从前一年的 889 万澳元上升至 1038 万澳元，利润率改善至 17.5%。公司的强大资产负债表表明，短期资产超过负债，且负债与股本比率在五年内从 14.5% 降至 4.4%，同时利息支付得到了良好覆盖，经营现金流显著超过债务水平。此外，XRF 经验丰富的管理层和董事会增强了其在行业波动中的运营稳定性。</p>
</div><ul>
<li>Jump into the full analysis health report here for a deeper understanding of XRF Scientific.</li>
<li>Learn about XRF Scientific's future growth trajectory here.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里深入了解 XRF Scientific 的全面分析健康报告。</li>
<li>了解 XRF Scientific 的未来增长轨迹。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9b63580b-4082-4ba3-bd48-ba43082e3621/chart/financial-position-analysis" alt="" original-src="https://images.simplywall.st/company/9b63580b-4082-4ba3-bd48-ba43082e3621/chart/financial-position-analysis"/></p>
<p>ASX:XRF Financial Position Analysis as at Aug 2025</p>
<div class="lb-trans"><p>截至 2025 年 8 月的 ASX:XRF 财务状况分析</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>关键要点</h2>
</div><ul>
<li>Jump into our full catalog of 455 ASX Penny Stocks here.</li>
<li>Seeking Other Investments? These 13 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.</li>
</ul>
<div class="lb-trans"><ul>
<li>在这里查看我们完整的 455 只 ASX 便士股票目录。</li>
<li>寻找其他投资？这 13 家公司在 COVID 之后生存并蓬勃发展，具备应对特朗普关税的正确要素。在您的投资组合感受到贸易战压力之前，了解原因。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章来自 Simply Wall St，内容具有一般性。<strong>我们提供基于历史数据和分析师预测的评论，仅使用无偏见的方法，我们的文章并不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也未考虑您的目标或财务状况。我们的目标是为您提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

AMA 集团及其他两个澳大利亚证券交易所的便士股票值得关注